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We have identified three truncating, two splice-site, and three missense variants at conserved amino acids in the CUL4B
gene on Xq24 in 8 of 250 families with X-linked mental retardation (XLMR). During affected subjects’ adolescence, a
syndrome emerged with delayed puberty, hypogonadism, relative macrocephaly, moderate short stature, central obesity,
unprovoked aggressive outbursts, fine intention tremor, pes cavus, and abnormalities of the toes. This syndrome was
first described by Cazebas et al., in a family that was included in our study and that carried a CUL4B missense variant.
CUL4B is a ubiquitin E3 ligase subunit implicated in the regulation of several biological processes, and CUL4B is the first
XLMR gene that encodes an E3 ubiquitin ligase. The relatively high frequency of CUL4B mutations in this series indicates
that it is one of the most commonly mutated genes underlying XLMR and suggests that its introduction into clinical
diagnostics should be a high priority.
From the Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom (P.S.T.; S.O.; S.E.; J.T.; A.B.; E.D.; C.S.; C.T.; T.A.; S.B.;
G.B.; J.C.; K.G.; K. Halliday; R.H.; K. Hills; A.J.; D.J.; A.M.; T.M.; J.P.; K.R.; D.R.; R. Shepherd; A.S.; J.V.; S. West; S. Widaa; R.W.; P.A.F.; M.R.S.); Cambridge
Institute of Medical Research (F.L.R.; U.M.; J.M.; Y.L.; M.B.) and Cancer Research UK Genetic Epidemiology Unit (D.F.E.), Cambridge, United Kingdom;
GOLD Service, Hunter Genetics and the University of Newcastle, New South Wales, Australia (J.B.; G.T.; M.P.); Department of Genetic Medicine, Women’s
and Children’s Hospital (M.S.; L.V.; J.G.), and Departments of Paediatrics and Molecular Biosciences, University of Adelaide (J.G.), Adelaide, Australia;
JC Self Research Institute of Human Genetics, Greenwood Genetic Center, Greenwood, SC (J.R.; A.K.S.; R.E.S.; C.E.S.); Department of Pediatrics, Division
of Genetics, Washington University School of Medicine, St. Louis, MO (R. Slaugh); North West Thames Regional Genetics Service, Northwick Park
Hospital, Harrow, United Kingdom (S.H.); Clinical Genetics, St. Michael’s Hospital, Bristol, United Kingdom (S.F.S.); Clinical Genetics, Oxford Radcliffe
Hospital, The Churchill, Oxford, United Kingdom (J.A.H.); and Clinical Genetics, St. Mary’s Hospital, Manchester, United Kingdom (J.C.-S.; B.K.)
Received October 6, 2006; accepted for publication November 20, 2006; electronically published January 4, 2007.
Address for correspondence and reprints: Prof. Michael R. Stratton, Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome
Campus, Hinxton, Cambridge, CB10 1SA. E-mail: mrs@sanger.ac.uk
* These two authors contributed equally to this work.
Am. J. Hum. Genet. 2007;80:345–352.  2007 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8002-0015$15.00
Mental retardation (MR) affects ∼1%–3% of the popula-
tion and is ∼30% more prevalent in males than in fe-
males.1 To date, mutations in 160 (∼6%) of the X-linked
genes annotated in the Vega Genome Browser have been
associated with an MR phenotype (for review, see the work
of Chelly et al.2 and Ropers and Hamel3). Traditionally,
families with X-linked MR (XLMR) have been divided into
syndromic and nonsyndromic categories. In nonsyn-
dromic XLMR, MR is the only clinical feature, whereas,
in syndromic XLMR, there are other associated clinical or
biochemical abnormalities. Recently, it has become clear
that this classification is too rigid and arbitrary. For ex-
ample, patients in most families with mutations in
RPS6KA3 have Coffin Lowry syndrome, but one family has
been reported with nonsyndromic XLMR.4
Each reported XLMR gene appears to be responsible for
only a small fraction of affected families; the exceptions
are FMR1 (MIM 309550), which accounts for ∼20% of fam-
ilies with XLMR, and ARX (MIM 300382), which is mu-
tated in ∼9.5% of X-linked families and ∼2.2% of small
families with multiple affected males (brother pairs).5,6
Therefore, despite considerable success in the identifica-
tion of XLMR genes, the XLMR in most affected families
has not been attributed to any of the known genes. Ge-
netic heterogeneity has hindered the pursuit of further
XLMR genes by conventional positional-cloning strate-
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Table 1. Identified CUL4B Variants
CUL4B Variant
Mutation
Class Family
No. of Affected
Individuals
No. of
Generations Control
Allele
Frequency
Identified in MR samples:
c.1007_1011delTTATA Deletion 42 7 2 … …
c.1162CrT; p.R388X Nonsense 307 3 2 … …
c.2566CrT; p.R856X Nonsense 43 8 3 … …
c.901–2ArG Splice 329 3 1 … …
c.2493GrA; p.T831T Splicea 363 3 3 … …
c.1714CrT; p.R572C Missense 180 6 2 … …
c.2234TrC; p.V745A Missense 64 4 2 … …
c.638CrT; p.T213I Missense 432 5 2 … …
Identified in control samples:
c.308TrC; p.L103P Missense … … … AC0302 1/639
c.732ArG; p.V244V Silent … … … AC0553 1/634
a Cryptic splice site.
gies, because genetic linkage information from different
families cannot be combined with confidence. As a result,
individual families with XLMR are mapped to large areas
of the X chromosome that contain substantial numbers
of genes, rendering the underlying mutations hard to
identify.
We commenced a systematic mutational screen of the
X chromosome in 250 families with multiple members
with MR, to provide an alternative strategy to positional
cloning. The approach is not dependent on mapping by
genetic linkage and is a direct search for putative disease-
causing mutations. Each family in the screen has a normal
karyotype by conventional 500 G-banding resolution and
is negative for an expansion of the trinucleotide repeat in
the FMR1 gene. For the 250 families, a causative mutation
was not found after prescreening of 61 known syndromic
and nonsyndromic XLMR genes. The families were in-
vestigated by bidirectional sequencing of 676 Vega-
annotated genes. In the course of the screen, we noted
truncating and missense variants in CUL4B (MIM 300304;
GenBank accession number NM_003588), in Xq24 (table
1).
CUL4B is a member of the family of cullin proteins that
function primarily as scaffold proteins for a series of ubi-
quitin-protein ligase complexes that regulate the degra-
dation of cellular proteins. The CUL4B gene is composed
of 22 exons and encodes a protein of 913 aa (GenBank
accession number NP_003579). The cullin domain is lo-
cated between amino acid residues 217 and 815 and is
characterized by a C-terminal globular domain (cullin ho-
mology domain) and a series of N-terminal repeats (cullin
repeats).
Three mutations that introduce premature termination
codons were identified (figs. 1 and 2). In family 42, there
is a c.1007_1011delTTATA deletion, which introduces a
translational frameshift, resulting in the inclusion of a
single novel amino acid and a premature termination at
codon 337. Genetic linkage analysis demonstrated that
the three affected male siblings in this family share a hap-
lotype between DXS1106 and DXS1073 on Xq22-Xq28,
which is consistent with the localization of CUL4B. It was
confirmed that the c.1007_1011delTTATA mutation seg-
regates in the three affected males and their mother. In
family 307, there is a p.R388X (c.1162CrT) nonsense
mutation that was found in the proband and his two af-
fected maternal uncles. In family 43, there is a p.R856X
(c.2566CrT) nonsense mutation. This family had linkage
data consistent with Xq24-q27.1, and the R856X mutation
was confirmed in all eight affected males.
Two families carried variants in splice sites, which alter
splicing such that the protein is prematurely truncated.
In family 329, a base change, 901–2ArG, was found. To
investigate the effect of this variant on splicing, CUL4B
exons 6–11 were amplified from patient and control lym-
phocyte cDNA. The 901–2ArG alteration results in ab-
errant splicing of the CUL4B transcript (fig. 3a). Sequence
analysis shows that the mutated exon 7 splice-acceptor
site is ignored, and, as a result, exon 7 (74 bp) is excluded
from the mature transcript. Removal of exon 7 results in
the introduction of a translational frameshift, with the
inclusion of 7 novel aa and a premature termination at
codon 308. The 901–2ArG change was found in the pro-
band and his two affected brothers.
In family 363, an apparently silent variant, p.T831T
(c.2493GrA), affecting the last base of exon 20, was found
(fig. 3b). In silico analysis indicated that this nucleotide
change weakens the consensus splice-donor site for intron
20 (BDGP: Splice Site Prediction by Neural Network). To
examine directly whether this variant has any affect on
splicing, CUL4B exons 18–22 were amplified from patient
and control lymphocyte cDNA. Sequence analysis of the
RT-PCR product shows that the splice-donor site of intron
20 is ignored, and two new cryptic TG/GT splice-donor
sites are activated. The major transcript used a cryptic do-
nor site 80 bp upstream in exon 20. The outcome is the
exclusion of 80 bp at the end of exon 20 from the CUL4B
transcript, with consequent introduction of a premature
translational termination at codon 806. A second minor
transcript used a cryptic donor site 65 bp upstream in exon
20. The deletion of the terminal 65 bp of exon 20 results
in the introduction of a premature termination at co-
don 811. Wild-type transcript was not observed. The
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Figure 2. a, Schematic representation of the genomic structure of CUL4B, with positions of mutations found in eight families with
XLMR. b, Schematic representation of the protein sequence. The cullin domain is marked, and the positions of the eight mutations are
indicated.
c.2493GrA change was found in the proband of family
363 and his affected nephew.
Three missense variants were identified in the screen.
In family 180, there is a p.R572C (c.1714CrT) change.
Residue R572 is highly conserved throughout evolution
(fig. 4) and is located within the cullin domain, and the
argininercysteine change is a nonconservative substitu-
tion. MR in family 180 has previously been mapped to
Xq23-Xq25, with a maximum LOD score of 2.8 at
DXS1212, which is compatible with the location of
CUL4B.7 The c.1714CrT change segregates with MR in
family 180, and the affected males share many phenotypic
features with others who carry truncating CUL4B muta-
tions, including tremor and pes cavus. Taken together, the
results strongly indicate that p.R572C (c.1714CrT) is the
mutation causing XLMR in family 180.
In family 64, a c.2234TrC change was found that gave
rise to the missense mutation p.V745A. Residue V745 is
highly conserved throughout evolution (fig. 4) and is lo-
cated within the cullin domain. Linkage was demon-
strated between DXS6064 in Xq23 and DXS1205 in
Xq27.1, which is consistent with the location of CUL4B.
The V745A variant was found in four affected males and
one obligate female and was absent in two unaffected
males.
In family 432, missense mutation p.T213I (c.638CrT)
was found. Residue T213 is conserved during evolution,
although not as extensively as residues R572 or V745 (fig.
4). Residue T213 is just outside the cullin domain. How-
ever, there is clearly conservation of amino acids imme-
diately adjacent to it, indicating that it is probably part
of a functional domain. Previous results have demon-
strated that family 432 exhibits genetic linkage to Xq24,
and the variant segregates with the disease in the two
available affected males and their mother. It is plausible
that c.638CrT (p.T213I) is responsible for XLMR in this
family. It is also possible that it is a rare variant. However,
we did not find another instance of this variant after se-
quencing exon 4 in 637 additional X chromosomes, al-
though these controls were ethnically unmatched to fam-
ily 432, which is of Asian descent. Further biological
studies may be required to unequivocally determine
whether the identified CUL4B missense variants are dis-
ease-associated or represent rare polymorphisms.
None of the proposed XLMR-causing variants was found
in a screen of the complete coding sequence and splice
sites of CUL4B in 637 normal X chromosomes, nor were
any other clearly truncating or splice-site variants found
among these controls. Indeed, CUL4B exhibits relatively
little variation in the general population. Two variants
were identified after the screening of 637 control chro-
mosomes (fig. 1b). A synonymous variant (c.732ArG;
p.V244V) was identified in a single female sample, and a
nonsynonymous variant (c.308TrC; p.L103P) was ob-
served in a single male sample. In contrast to the likely
disease-causing variants found in the families with XLMR,
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Figure 3. RT-PCR analysis. a, Analysis of family 329, demonstrating the skipping of exon 7 in the CUL4B transcript. b, Analysis of
family 363, showing deletion of the terminal 80 bp of exon 20, which results from the activation of a cryptic splice-donor site upstream
from the normal donor site.
residue L103 is poorly conserved through evolution,
and it is likely that these variants represent rare
polymorphisms.
The main clinical features of the syndrome were first
described in a single family by Cabezas et al.7 The clinical
features of this family and the seven additional families
with CUL4B mutations are summarized in table 2, and the
pedigrees are presented in figure 1. Seven families were
white, and one was of Asian descent. Affected individuals
from families 42, 43, and 363 are presented in figure 5.
There were 39 affected males, with variable clinical data
available for 28. Five of them were children younger than
15 years at their last assessment; the remainder of the
affected individuals were aged 16–56 years.
All the males had an intellectual disability. This was
usually moderate but varied widely, such that some men
were institutionalized and others were able to live semi-
independently. Speech delay was evident in early child-
hood and remained disproportionately severe given the
degree of intellectual impairment. In adults, speech was
very limited or nonexistent; nevertheless, affected indi-
viduals could understand simple commands and were of-
ten cooperative in tasks. Short outbursts of aggression
were common. Some were provoked, but many were not.
They ranged from shouting, stamping, and running away
to smashing windows and furniture, punching, and at-
tempted strangulation.
Several neurological features were evident—notably, a
fine intention tremor that was seen in the hands, with
some impairment of motor activities. Seizures, usually sin-
gle febrile fits, were common in young children but un-
common in adults. Ataxia was sufficient to suggest a di-
agnosis of Angelman syndrome (MIM 105830) in one
child but was usually regarded as clumsiness in adults.
Some unexplained wasting of the calf muscles, with re-
tained tendon reflexes, and pes cavus were seen.
A physical habitus of short stature and central obesity
was observed in some affected males and was often ac-
companied by gynecomastia and striae. Puberty was de-
layed, and abnormalities of the genital tract were reported,
including undescended and/or small testes, hypospadias,
and small penis. The average adult height was in the 5th
percentile, and the average head circumference was in the
97th percentile. The feet were often noted to be small with
abnormal toes and a wide sandal gap. Diagnoses of Prader-
Willi syndrome (MIM 176270), Bo¨rjeson-Forssman-
Lehman syndrome (MIM 301900), and Wilson-Turner
syndrome (MIM 309585) had all been considered. Nu-
merous biochemical investigations and magnetic reso-
nance imaging and CT scans showed no abnormalities
except for a porencephalic cyst (table 2). The known het-
erozygote females were essentially normal, except for one
who had borderline intelligence; one 12-year-old with
multiple tics, attention deficit disorder, and a fine tremor;
one with severe recurrent alopecia; and one with achalasia
of the cardia that required surgery. Overall, the only con-
sistent feature in all affected individuals was MR, but the
presence of relative macrocephaly, short stature, obesity,
genital tract abnormalities, tremor, aggressive outbursts,
seizures, and pes cavus are indicative of the syndrome
associated with mutations in CUL4B.
CUL4B is a component of the ubiquitin system. Ubi-
quitin-dependent proteolysis is a fundamental cellular
mechanism for regulating protein activity.8 It is implicated
in a diverse set of biochemical processes, including signal
transduction, transcription receptor down-regulation, and
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Table 2. Clinical Features in Affected Males of Eight
Families with Mutations in CUL4B
Age Period and Clinical Feature(s)
No. of Affected
Males with
Feature/Total No.
of Affected Males
Infancy:
Normal pregnancy and birth 18/18
Birth weight !10th percentile 11/15
Childhood:
Motor delay (walking at or after 2 years) 5/5
Speech delay 18/18
Seizures (before age 2 years) 8/11
Adulthood:
Height !10th percentile 7/11
Head circumference 197th percentile 8/11
MR: 22/22
Mild 4/18
Moderate 11/18
Severe 7/18
Impaired speech and/or nonverbal
communication 11/15
Aggressive outbursts 12/15
Tremor 11/13
Obesity, central 15/19
Abnormal toes, with wide 1–2 gap 11/13
Small feet 7/14
Pes cavus 7/8
Wasted lower-leg muscles 7/12
Small testes 10/15
Gynecomastia 7/10
Prominent lower lip 6/17
Gait ataxia 6/12
Kyphosis 3/18
NOTE.—In addition, there were single cases of pes planus, inguinal
hernia, micropenis, strabismus, cataracts, keratoconus, sleep apnea,
hemiplegia, porencephalic cyst, and acanthosis nigricans.
Figure 4. Alignment of available CUL4B protein sequences, showing the conservation of amino acid residues altered by the missense
mutations. Accession numbers in parentheses are from the Ensembl Genome Browser.
endocytosis and has been implicated in regulation of the
cell cycle, immune response, development, and pro-
grammed cell death. The proteolytic effects of ubiquitin-
ation are the most extensively characterized, but there is
also evidence that it can influence activities of proteins
through processes other than degradation.9–14
Ubiquitination generally results from the formation of
a peptide bond between the C-terminus of the 76-aa ubi-
quitin peptide and an amino group of a substrate lysine
residue. The process of ubiquitination involves several en-
zymatic activities. A ubiquitin-activating enzyme (E1) ac-
tivates the ubiquitin peptide in an ATP-dependent reac-
tion by forming an athioester bond with the C-terminal
glycine of ubiquitin. The ubiquitin is then transferred to
a specific sulfhydryl group on a ubiquitin-conjugating en-
zyme (E2). A ubiquitin-protein ligase (E3) then transfers
the activated ubiquitin from E2 to a lysine residue of a
bound substrate forming a peptide bond. The substrate
specificity of the process is determined predominantly by
E3 ligases, which bind both the protein substrate and the
cognate E2. Once the polyubiquitin chain has been as-
sembled on a protein substrate by the cooperation of E1,
E2, and E3 enzymes, the target protein is recognized and
degraded by the 26S proteasome.15
A large number of E3s are found in mammalian cells.
However, all known E3s have one of three structural el-
ements. These are the ∼350-aa HECT domain (homolo-
gous to E6-AP carboxy terminus), the RING (really inter-
esting new gene) finger, and the U-box domain.16–18 In
turn, there are two classes of RING E3s. In one class, the
E3 consists solely of the RING-finger protein itself. For this
class, the RING E3 together with E2 is sufficient for ubi-
quitination. In the second class of RING E3, the RING-
finger protein is part of a multisubunit protein complex.
The cullin family of proteins constitute one of the other
subunits of the complex and, by associating with the
RING-finger protein and a cognate E2, form the integral
catalytic core necessary for ubiquitination.
Cullin 4 (CUL4) is a conserved core component of a
class of ubiquitin E3 ligases that also contains the UV-
damaged DNA-binding protein 1 (DDB1) and RING-finger
protein ROC1 (also called “RBX1” or “HRT1”). There are
two paralogues in mammals, CUL4A and CUL4B. CUL4A
and CUL4B are coexpressed in many cell types, and the
functional differences between them remain unclear. The
specific targets of CUL4B are only partially understood and
may overlap with other E3 ubiquitin ligases. There is evi-
dence that CUL4-containing E3 ligase complexes regulate
the proteolysis of the replication-licensing protein CDT1
in response to UV or gamma-irradiation, that the CUL4A/
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Figure 5. a, b, and d, Three half brothers from family 42 (pedigree designations IV-1, IV-2, and IV-3, respectively), aged 21, 18, and
15 years, respectively. c, Feet of IV-2, showing a wide sandal gap and small size. e and f, Individual IV-2 from family 43, at ages 4
mo (e) and 4 years (f). g, Features of an affected cousin, IV-4. h, i, and j, Individual IV-1 from family 363 at age 6 years, showing
gynecomastia (h and i), and at age 13 years, showing splayed toes with a wide sandal gap (j). k, l, and m, Uncle (III-4) of IV-1 from
family 363, showing central obesity (k), upper dorsal kyphosis (l), and micropenis (m).
DDB1 complex regulates the proteolysis of c-Jun and
DDB2, and that CUL4 E3 ligase plays a critical role in
regulating G1 cell-cycle progression through degradation
of cyclin E.19,20
It is of interest that the abrogation of CUL4B functions
results in MR with a relatively limited array of other clin-
ical features. It may be that the E3 ligase of CUL4B is
directed at a limited set of protein targets, and, therefore,
most developmental processes proceed relatively nor-
mally. Alternatively, it is possible that there is substantial
redundancy in the ubiquitin E3 ligase system, such that
other ubiquitin ligases (e.g., CUL4A) duplicate many func-
tions of CUL4B. In particular, there has been no indication
of cancer susceptibility in families with XLMR due to
CUL4B mutations, despite the likely involvement of
CUL4B in processes relating to DNA repair, replication,
and cell-cycle progression.
Mutated genes encoding proteins with diverse biologi-
cal functions have previously been shown to be involved
in XLMR. Although a truncating mutation of UBE2A/
HR6A, which encodes an E2 ubiquitin-conjugating en-
zyme, was recently reported in a single family with
XLMR,21 CUL4B is the first ubiquitin E3 ligase mutated in
XLMR. Abnormalities of E3 ligases, however, have been
reported in other human genetic diseases. Mutations in
the ubiquitin-protein ligase E3A gene (UBE3A) on chro-
mosome 15q underlie a subset of Angelman syndrome,22,23
in which MR is a notable clinical feature, and abnormal-
ities of other E3 ligases have been shown to cause recessive
juvenile Parkinson disease (MIM 600116) (caused by
mutation in PARK2),24 autoimmune polyendocrinopathy
syndrome type 1 (MIM 240300) (caused by mutation in
AIRE),25 and von Hippel-Lindau disease (MIM 193300)
(caused by mutation in VHL).26
Further prevalence studies are now needed to estimate
more precisely the contribution of mutations in CUL4B
to XLMR. However, our finding of eight families with
XLMR (3% of the 250 screened) that have CUL4B muta-
tions that are likely disease associated indicates that this
may be one of the most frequently mutated genes un-
derlying XLMR (for comparison, the currently most fre-
quently mutated known XLMR gene is DLG3, in which
we have found mutations in five families with XLMR).
Moreover, the association of additional clinical features as
part of the syndrome associated with CUL4B mutations
suggests that targeted implementation of genetic testing
for CUL4B mutations may be practical and have substan-
tial clinical utility.
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